These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31100307)

  • 1. Interleukin 6-triggered ataxia-telangiectasia mutated kinase activation facilitates epithelial-to-mesenchymal transition in lung cancer by upregulating vimentin expression.
    Jiang YN; Ni XY; Yan HQ; Shi L; Lu NN; Wang YN; Li Q; Gao FG
    Exp Cell Res; 2019 Aug; 381(2):165-171. PubMed ID: 31100307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin 6 trigged ataxia-telangiectasia mutated activation facilitates lung cancer metastasis via MMP-3/MMP-13 up-regulation.
    Jiang YN; Yan HQ; Huang XB; Wang YN; Li Q; Gao FG
    Oncotarget; 2015 Dec; 6(38):40719-33. PubMed ID: 26528698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ataxia-telangiectasia mutated activation mediates tumor necrosis factor-alpha induced MMP-13 up-regulation and metastasis in lung cancer cells.
    Yan HQ; Zhang D; Shi YY; You X; Shi L; Li Q; Gao FG
    Oncotarget; 2016 Sep; 7(38):62070-62083. PubMed ID: 27556690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway.
    Shen M; Xu Z; Xu W; Jiang K; Zhang F; Ding Q; Xu Z; Chen Y
    J Exp Clin Cancer Res; 2019 Apr; 38(1):149. PubMed ID: 30961670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ginsenoside Rg3 inhibits epithelial-mesenchymal transition (EMT) and invasion of lung cancer by down-regulating FUT4.
    Tian L; Shen D; Li X; Shan X; Wang X; Yan Q; Liu J
    Oncotarget; 2016 Jan; 7(2):1619-32. PubMed ID: 26636541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vimentin activation in early apoptotic cancer cells errands survival pathways during DNA damage inducer CPT treatment in colon carcinoma model.
    Chakraborty S; Kumar A; Faheem MM; Katoch A; Kumar A; Jamwal VL; Nayak D; Golani A; Rasool RU; Ahmad SM; Jose J; Kumar R; Gandhi SG; Dinesh Kumar L; Goswami A
    Cell Death Dis; 2019 Jun; 10(6):467. PubMed ID: 31197132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer.
    Chowdhury P; Dey P; Ghosh S; Sarma A; Ghosh U
    BMC Cancer; 2019 Aug; 19(1):829. PubMed ID: 31438892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resveratrol inhibits TGF-β1-induced epithelial-to-mesenchymal transition and suppresses lung cancer invasion and metastasis.
    Wang H; Zhang H; Tang L; Chen H; Wu C; Zhao M; Yang Y; Chen X; Liu G
    Toxicology; 2013 Jan; 303():139-46. PubMed ID: 23146760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer.
    Ma K; Fan Y; Dong X; Dong D; Guo Y; Wei X; Ning J; Geng Q; Wang C; Hu Y; Li M; Niu W; Li E; Wu Y
    Oncotarget; 2017 Jun; 8(24):38825-38840. PubMed ID: 28418915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxia-telangiectasia mutated/NF-kappaB pathway activation.
    Yan HQ; Huang XB; Ke SZ; Jiang YN; Zhang YH; Wang YN; Li J; Gao FG
    Cancer Sci; 2014 Sep; 105(9):1220-7. PubMed ID: 24988892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of histamine H4 receptors decreases epithelial-to-mesenchymal transition progress by inhibiting transforming growth factor-β1 signalling pathway in non-small cell lung cancer.
    Cai WK; Hu J; Li T; Meng JR; Ma X; Yin SJ; Zhao CH; He GH; Xu GL
    Eur J Cancer; 2014 Apr; 50(6):1195-206. PubMed ID: 24447834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BTBD7 Downregulates E-Cadherin and Promotes Epithelial-Mesenchymal Transition in Lung Cancer.
    Shu J; Wang L; Han F; Chen Y; Wang S; Luo F
    Biomed Res Int; 2019; 2019():5937635. PubMed ID: 31886230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor cell heterogeneity in Small Cell Lung Cancer (SCLC): phenotypical and functional differences associated with Epithelial-Mesenchymal Transition (EMT) and DNA methylation changes.
    Krohn A; Ahrens T; Yalcin A; Plönes T; Wehrle J; Taromi S; Wollner S; Follo M; Brabletz T; Mani SA; Claus R; Hackanson B; Burger M
    PLoS One; 2014; 9(6):e100249. PubMed ID: 24959847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of hnRNP K with MAP 1B-LC1 promotes TGF-β1-mediated epithelial to mesenchymal transition in lung cancer cells.
    Li L; Yan S; Zhang H; Zhang M; Huang G; Chen M
    BMC Cancer; 2019 Sep; 19(1):894. PubMed ID: 31492158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation-mediated SOD-2 upregulation contributes to epithelial-mesenchymal transition and migration of tumor cells in aflatoxin G
    Yi L; Shen H; Zhao M; Shao P; Liu C; Cui J; Wang J; Wang C; Guo N; Kang L; Lv P; Xing L; Zhang X
    Sci Rep; 2017 Aug; 7(1):7953. PubMed ID: 28801561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The over expression of long non-coding RNA ANRIL promotes epithelial-mesenchymal transition by activating the ATM-E2F1 signaling pathway in pancreatic cancer: An in vivo and in vitro study.
    Chen S; Zhang JQ; Chen JZ; Chen HX; Qiu FN; Yan ML; Chen YL; Peng CH; Tian YF; Wang YD
    Int J Biol Macromol; 2017 Sep; 102():718-728. PubMed ID: 28344092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic 8-hydroxydeoxyguanosine inhibited metastasis of pancreatic cancer through concerted inhibitions of ERM and Rho-GTPase.
    Park JM; Han YM; Jeong M; Chung MH; Kwon CI; Ko KH; Hahm KB
    Free Radic Biol Med; 2017 Sep; 110():151-161. PubMed ID: 28602912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rubus idaeus L Inhibits Invasion Potential of Human A549 Lung Cancer Cells by Suppression Epithelial-to-Mesenchymal Transition and Akt Pathway In Vitro and Reduces Tumor Growth In Vivo.
    Chu SC; Hsieh YS; Hsu LS; Chen KS; Chiang CC; Chen PN
    Integr Cancer Ther; 2014 May; 13(3):259-73. PubMed ID: 24335666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
    Chen J; Li N; Liu B; Ling J; Yang W; Pang X; Li T
    Life Sci; 2020 May; 248():117469. PubMed ID: 32109485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.